Severe Hypoglycemia from <i>Helicobacter Pylori</i> Triple‐Drug Therapy and Insulin Detemir Drug Interaction

Otsuka, Shelley

doi:10.1002/phar.1228

Cited by 6 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our patient was not on any oral hypoglycaemic agents although she was on omeprazole. Omeprazole may be implicated in promoting hypoglycaemia; [12] however, this appears to be in combination with H. pylori triple drug therapy and is not a recognised adverse effect of long term isolated omeprazole use. …”

Section: Discussionmentioning

confidence: 99%

Cotrimoxazole-Induced Hypoglycaemia in a Patient with Churg-Strauss Syndrome

Senanayake

Mukhtar²

2013

Case Reports in Endocrinology

View full text Add to dashboard Cite

Cotrimoxazole is a commonly used antimicrobial agent which is traditionally indicated in the management of pneumocystis infection of which HIV and immunosuppressed individuals are at high risk. Furthermore, it can be used on the long term for prophylactic indications. Hypoglycaemia following commencement of cotrimaoxazole is a rare adverse effect which was first described in 1988. We describe a case of hypoglycaemia shortly following initiation of cotrimoxazole indicated as long-term prophylaxis on a background of Churg-Strauss syndrome. The patient was symptomatic for hypoglycaemia despite simultaneous use of high-dose prednisolone; however, the hypoglycaemia did not require a hospital admission. We will explore the risk factors, monitoring requirements, and the mechanism by which co-trimoxazole induces hypoglycaemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Cotrimoxazole-Induced Hypoglycaemia in a Patient with Churg-Strauss Syndrome

Senanayake

Mukhtar²

2013

Case Reports in Endocrinology

View full text Add to dashboard Cite

show abstract

“…However, several case reports have revealed hypoglycemia can occur when these regiments are in patients taking diabetes medication [ 11 ]. Another case report described an 82-year-old man with type 2 diabetes using insulin detemir who experienced severe hypoglycemia during treatment for H. pylori infection [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Triple therapy for Helicobacter pylori eradication and the risk of hypoglycemia in patients with diabetes: a population-based cohort study

Chang,

Chen

et al. 2023

BMC Public Health

View full text Add to dashboard Cite

The incidence of type 2 diabetes mellitus has risen globally, from 108 million cases in 1980 to 422 million cases in 2014. Although controlling glycemic levels in patients with diabetes is crucial, insulin and sulfonylureas can cause hypoglycemic episodes and even potentially fatal events such as comas, seizures, life-threatening arrhythmias, and myocardial infarctions. Several antibiotics have been documented to cause hypoglycemic episodes; the use of antibiotics along with insulin or sulfonylureas might further increase the risk of hypoglycemia. Therefore, researchers must determine which antibiotics carry a risk of inducing severe hypoglycemic events. The prevalence of H. pylori infection remains high in most countries, and the infection is often treated with triple therapy involving amoxicillin, clarithromycin, and a proton pump inhibitor (PPI). Several case reports have reported that hypoglycemia can occur when used with patients who also take diabetes medication. Therefore, we hypothesized that patients with diabetes have an increased risk of hypoglycemic episodes when being treated with triple therapy for H. pylori infection. By analyzing medical records from Taiwan’s National Health Insurance Research Database, we found a significant association between hypoglycemia and triple therapy treatment for diabetic patients with peptic ulcer disease. Prescribing triple therapy to patients with diabetes and peptic ulcers significantly increased the risk of a hypoglycemic episode (adjusted odds ratio [aOR] = 1.75, 95% confidence interval [CI]: 1.64 to 1.88, P < 0.001). Similarly, the highest aOR (5.77, 95% CI 4.82 to 6.92) was found in patients with diabetes and peptic ulcers who had hypoglycemic episodes within 30 days after triple therapy treatment. Many patients with diabetes require H.pylori eradication for peptic ulcer treatment, and vigilance toward the risk of hypoglycemia in this population is thus necessary.

show abstract

“…However, several case reports have revealed hypoglycemia can occur when these regiments are used alongside diabetes medication. Another case report showed an 82-year-old man with type 2 diabetes experienced severe hypoglycemia during treatment for H. pylori infection using insulin detemir as a glucose-lowering agent [7].…”

Section: Introductionmentioning

confidence: 99%

Triple therapy for Helicobacter pylori eradication and the risk of hypoglycemia in patients with diabetes: A population-based cohort study

Chang

Chen

et al. 2023

Preprint

View full text Add to dashboard Cite

The incidence of type 2 diabetes mellitus has risen globally, from 108 million cases in 1980 to 422 million cases in 2014. Although controlling glycemic levels in patients with diabetes is crucial, improper management can lead to hypoglycemic episodes and even potentially fatal events such as comas, seizures, life-threatening arrhythmias, and myocardial infarctions. Several antibiotics have been documented to cause hypoglycemic episodes; the use of antibiotics along with certain diabetic medications might further increase the risk of hypoglycemia. Therefore, researchers must determine which treatments against which types of infection carry a risk of inducing severe hypoglycemic events. The prevalence of H. pylori infection remains high in most countries, and the infection is often treated with triple therapy involving amoxicillin, clarithromycin, and a proton pump inhibitor (PPI). Several case reports have reported that hypoglycemia can occur when any one of them are used with patients who also take diabetes medication. Therefore, we hypothesized that patients with diabetes might experience hypoglycemic episodes when being treated with triple therapy for H. pylori infection. By analyzing medical records from Taiwan’s National Health Insurance Research Database, we found a significant association between hypoglycemia and triple therapy treatment for diabetic patients with peptic ulcer. Prescribing triple therapy to patients with diabetes and peptic ulcers significantly increase the risk of a hypoglycemic episode (adjusted odds ratio [aOR] = 1.75, 95% confidence interval [CI]: 1.64 to 1.88, P < 0.001). Similarly, the highest aOR (5.77, 95% CI 4.82 to 6.92) was found in patients with diabetes and peptic ulcers who had hypoglycemic episodes within 30 days after triple therapy treatment. Many patients with diabetes require H.pylori eradication for peptic ulcer treatment, and vigilance toward the risk of hypoglycemia in this population is thus necessary.

show abstract

Severe Hypoglycemia from Helicobacter Pylori Triple‐Drug Therapy and Insulin Detemir Drug Interaction

Cited by 6 publications

References 17 publications

Cotrimoxazole-Induced Hypoglycaemia in a Patient with Churg-Strauss Syndrome

Cotrimoxazole-Induced Hypoglycaemia in a Patient with Churg-Strauss Syndrome

Triple therapy for Helicobacter pylori eradication and the risk of hypoglycemia in patients with diabetes: a population-based cohort study

Triple therapy for Helicobacter pylori eradication and the risk of hypoglycemia in patients with diabetes: A population-based cohort study

Contact Info

Product

Resources

About